ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2326

Discovery of a Highly Potent, Selective Reversible Covalent  Inhibitor of JAK3 Kinase

Ronald J. Hill1, Angelina Bisconte1, J. Michael Bradshaw1, Ken Brameld2, Eun Ok Kim1, Xiaoyan Li2, Tim Owens2, Erik Verner2 and David M. Goldstein2, 1Biology, Principia Biopharma, South San Francisco, CA, 2Chemistry, Principia Biopharma

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Auto-immunity, inflammation and kinase, Janus kinase (JAK), T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: T-cell Biology and Targets in Autoimmune Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Targeting of the JAK-STAT pathway has been shown to be efficacious for treatment of patients with rheumatoid arthritis through the successful use of pan-JAK inhibitors in clinical trials. To date, lack of selective JAK3 inhibitors has hindered the assessment of the role of JAK3 in autoimmune disorders. A JAK3 inhibitor has the potential benefit of alleviating undesirable side effects of JAK1 and JAK2 inhibition such as dyslipidemia and suppression of hematopoiesis, respectively. A new approach is presented to achieve potent, selective and durable inhibition of JAK3 by application of Principia’s reversible covalent platform targeting a cysteine residue in the active site of JAK3 that is absent from other JAK family members. Ability of these inhibitors to block IL-2 and IL-4 signaling is presented.

Methods: Enzyme potencies were measured using the Caliper platform at Nanosyn Inc. (Santa Clara, CA). IL-2 stimulated phospho-STAT5 was measured in Ficoll separated human peripheral blood mononuclear cells (PBMCs) by flow cytometry. IL-4 stimulated STAT6 activation was measured in Ramos B cells based on a STAT6 reporter assay (Invitrogen, Madison, WI). Kinase profiling was performed at DiscoveRx (San Diego, CA).

Results: We have developed a series of molecules that are highly potent and selective for JAK3. Compound 1 inhibited JAK3 enzymatic activity with an IC50 of 0.5 ± 0.3 nM, but not JAK1, JAK2, or TYK2 up to a concentration of 5 uM.  The selectivity among other kinases within the Cys sub-family was also high with no inhibition exceeding 60% at 1 uM. Profiling against a panel of 442 kinases confirmed the exceptional selectivity of the series. Compound 1 forms a durable yet reversible Cys interaction with JAK3 in biochemical assays with a dissociation half-life of 9 hours.

In cell-based assays, Compound 1 completely inhibited IL-2 stimulated STAT5 phosphorylation (IC50 = 206 ± 11 nM) in hPBMCs, IL-4 stimulated STAT6 phosphorylation (IC50 = 58 ± 10 nM) in Ramos B cells and IL-2 driven IFNgamma secretion (IC50 = 248 ± 8 nM) in hPBMCs. IL-6 stimulated STAT3 phosphorylation was not inhibited up to 5 uM indicating complete cellular selectivity for JAK3 over JAK1. In addition, NFAT activation downstream of TCR stimulation in Jurkat T cells was not blocked.

Conclusion: Compound 1 is a potent, selective and durable inhibitor of JAK3 and has the potential to be an efficacious treatment for rheumatoid arthritis or other T cell driven diseases with a potential for differentiation from pan-JAK inhibitors.


Disclosure:

R. J. Hill,

Principia Biopharma,

3;

A. Bisconte,

Principia Biopharma,

3;

J. M. Bradshaw,

Principia Biopharma,

3;

K. Brameld,

Principia Biopharma,

3;

E. O. Kim,

Principia Biopharma,

3;

X. Li,

Principia Biopharma,

3;

T. Owens,

Principia Biopharma,

3;

E. Verner,

Principia Biopharma,

3;

D. M. Goldstein,

Principia Biopharma,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/discovery-of-a-highly-potent-selective-reversible-covalent-inhibitor-of-jak3-kinase/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology